Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Respiratory Disease Vaccine Market’s Growth Trajectory From 2025 To 2034?

The market size of the respiratory disease vaccine has experienced slight growth in the past few years. The growth trajectory indicates an increase from $69.99 billion in 2024 to $70.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 0.1%. This past expansion can be linked to the increasing occurrences of respiratory illnesses, heightened awareness about public vaccinations, public health campaigns, and amplified demand for potent and more bearable vaccines.

The market size for respiratory disease vaccines is anticipated to observe consistent expansion in the upcoming years, reaching $77.48 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 2.6%. This predicted growth during the forecast period is linked to factors such as an aging population, increased expenditure on healthcare, investments in vaccines, and readiness for pandemics. Upcoming trends expected during this time span include the invention of new vaccines, joint research initiatives, progress in vaccine development, and the approval of drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What External and Internal Drivers Are Contributing to the Growth of theRespiratory Disease Vaccine Market?

The uptick in tuberculosis cases is anticipated to propel the progress of the respiratory disease vaccine market. Tuberculosis (TB) is a type of respiratory disease brought about by the bacteria Mycobacterium tuberculosis, which predominantly affects the lungs and has the potential to impact other organ systems in the body, resulting in varied complications. The upsurge in tuberculosis cases can spur efforts towards the creation and distribution of respiratory disease vaccines to curb TB’s spread. For example, in November 2023, the US-based government agency Centers for Disease Control and Prevention reported 8,331 cases of tuberculosis in 2022 in the United States, representing an increase of 5.9% in case count from 2021. The incidence rate escalated to 2.5 cases per 100,000 people, a 5.5% increase from the preceding year. Consequently, the rising prevalence of tuberculosis is projected to be a major driving force for the respiratory disease vaccine market.

What Segment Types Define the Respiratory Disease Vaccine Market Structure?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Respiratory Disease Vaccine Market?

Leading firms in the respiratory disease vaccine market are shifting their focus towards the development of novel products to increase their effectiveness and offer superior solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical corporation based in the U.S., gained approval from the Food and Drug Administration (FDA) for its product ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. It is designed to avert lower respiratory tract disease engendered by the respiratory syncytial virus in people aged 60 years and above. ABRYSVO is a non-adjuvanted vaccine that consists of a couple of preF proteins that are specifically designed to optimize immunity against RSV A and B variants and its safety and effectiveness have been substantiated clinically.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What Is the Definition of the Respiratory Disease Vaccine Market?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model